Ramsay Health Care

Milton James

Ophthalmologists have seen a progression in cyclophotocoagulation (CPC) with each generation becoming more doctor- and patient-friendly. CPC has traditionally been used as a last resort treatment when all other alternatives were unsuccessful. This reasoning is based on out-of-date technology (cyclocryotherapy) and investigations of patients with advanced glaucoma. Due to its ergonomics, cost, and efficiency, diode CPC is the favored method of cilioablative therapy in the twenty-first century. Diode CPC is far more accurate and causes less collateral tissue damage than earlier cyclodestructive methods.

Transscleral CPC has achieved clinically relevant success rates in cases of refractory glaucoma after penetrating keratoplasty, uveitic glaucoma, and glaucoma after intravitreal silicone oil, refractory pediatric glaucoma, and failed tube-shunt procedures, in addition to treating severe end-stage glaucoma. Under challenging instances, wherein additional interventions are not viable or individuals with a weakened overall medical state preclude invasive surgery, the procedure has also proved beneficial as a primary treatment for glaucoma.

Eyes with severe glaucoma-related difficulties are suitable for treatment, but patients must be aware that their postoperative vision may be slightly worse than their pretreatment vision, depending on their preoperative vision and diagnosis. Only a small percentage of the time does visual acuity improve after surgery.

Treatment is less likely to help the eyes with a total blockade of outflow because the postoperative Intraocular pressure (IOP) would need to drop to manageable levels with a virtually complete stoppage of aqueous inflow. Although laser CPC is frequently performed in the office, it necessitates profound local (typically retrobulbar) or general anesthesia in the OR setting; the patient must be agreeable and medically fit for this procedure.

Endoscopic CPC is a recently developed procedure that allows for direct observation of the ciliary processes while they are being treated. For this intraoperative operation, probes of various gauge sizes (18, 19, 20, and 23) are available.

What’s more, endoscopic cyclophotocoagulation (ECP) is used to treat glaucoma that has become resistant and some cases of neovascular glaucoma (NVG). Additionally, the operation has been used as an alternative to combine cataract and glaucoma filtration surgery for eyes with glaucoma undergoing phacoemulsification. It has also been utilized for phacoemulsification in eyes with medically managed glaucoma. The goal of the last group is to decrease the patient’s reliance on medical glaucoma treatment. ECP is a surgical technique that requires a lot of time and effort. It, like the transscleral technique, necessitates substantial local (typically peribulbar) or general anaesthesia in an OR setting, as well as the standard patient participation and medical clearance criteria.

ECP allows surgeons to observe the ablation’s location and effect on target tissue in real-time, allowing them to fine-tune treatment parameters to optimize the tissue’s reaction while sparing the underlying pigmented tissue.

Patients should comprehend the strategy, prerequisites, benefits, risks, and alternatives, just as they do with any surgery, and give informed consent for the proposed procedure. Surgeons should advise patients about the possibility of postoperative pain and visual loss when doing transscleral CPC. Patients should also be aware that achieving the required glaucoma control may require more than one transscleral CPC therapy session.

The purpose of transscleral CPC is to lower IOP by reducing aqueous humour input. Less aqueous humour is generated when therapy ablates a sufficient portion of the ciliary processes. Although the quantity and duration of the decline have not been defined, this alteration is most likely permanent. A higher reduction in aqueous output follows more extensive damage. The IOP will decrease if there is no new increments in resistance to aqueous outflow through the trabecular meshwork and uveoscleral pathway.

The surgeon should apply a strong, long-lasting cycloplegic (e.g., atropine) and a topical steroid, as well as a soft eye patch, to protect the eye until the local anaesthesia wears off at the end of CPC procedures. Following ECP, the eyes should be treated with a specific antibiotic. The cycloplegic b.i.d. and steroid drops q.i.d. should be administered over a course of at least two weeks and longer if required. Severe postoperative inflammation may necessitate the administration of stronger steroids. After one week, the antibiotic administered t.i.d. to q.i.d. may be discontinued. Pain can be relieved by acetaminophen. Analgesics with a higher potency are rarely required. The usage of an ice pack for a short period of time may be beneficial to some people. Patients are watched for several months after the procedure to ensure a safe recovery, with initial follow-up ranging from one to seven days depending on the severity of their pretreatment IOP and the diagnosis. Following that, they are seen less frequently.

Patients are often able to minimize topical and systemic medical glaucoma medication after ciliary ablation, but most require continued medical therapy to achieve optimal IOP control. For eyes that had a poor or complete response to the first CPC surgery, a second transscleral CPC treatment is generally beneficial. Years after the initial treatment, this requirement may arise. The success rates for repeat surgeries have not been quantified; however, they are most likely lower than after the original intervention.